KAI1基因在甲状腺乳头状癌组织中的表达及意义

目的 探讨KAI1基因在人类甲状腺乳头状癌组织中的表达及其与临床病理特征和预后的关系.方法 应用Real Time-PCR检测21例甲状腺乳头状癌组织及相应的21例癌旁正常组织和7例甲状腺良性病变组织中KAI1 mRNA的表达情况,同时应用免疫组织化学法检测60例甲状腺乳头状癌组织和20例甲状腺腺瘤组织中KAI1蛋白的表达水平.结果 KAI1 mRNA在甲状腺乳头状癌组织中的表达量显著高于癌旁正常甲状腺组织（P＜0.05）及甲状腺良性病变组织（P＜0.05）.KAI1蛋白在甲状腺乳头状癌组织中的阳性表达率为68.3%,在甲状腺腺瘤组织中阳性表达率为25%,二者差异有高度统计学意义（P＜0.01）.KAI1蛋白在甲状腺乳头状癌无淋巴结转移组的阳性表达率要高于有淋巴结转移组,差异有统计学意义（P＜0.05）;KAI1蛋白在男性和女性患者中的阳性表达率差异无统计学意义（P＞0.05）.KAI1蛋白的表达与患者的年龄、肿瘤大小、TNM分期及包膜侵犯均无关（P＞0.05）.结论 KAI1 mRNA及其蛋白的异常表达与甲状腺乳头状癌的发生、发展有关,有助于甲状腺乳头状癌的治疗和预后判断.

KAI1 gene expression in papillary thyroid carcinoma and its significance

Objective To explore the relationship between KAI1 gene expression in papillary thyroid carcinoma and clinicopathological features and prognosis. Methods KAI1 mRNA expression was detected by Real Time Polymerase Chain Reaction in 21 cases papillary thyroid carcinoma tissues and 21 cases adjacent normal tissues, as well as 7 cases benign thyroid disease tissues. KAI1 protein expression was detected by immunohistochemisty in 60 cases papillary thyroid carcinoma tissues and 20 cases thyroid adenoma tissues. Results KAI1 mRNA expression in papillary thyroid carcinoma was significantly higher than that in adjacent normal tissues (P ＜ 0. 05) and benign thyroid lesion tissues (P ＜ 0. 05). Positive expression rate of KAI1 protein was 68. 3% in papillary thyroid carcinoma and 25% in thyroid adenoma tissues. The difference was statistically significant (P ＜0. 01). In papillary thyroid carcinoma, positive expression rate of KAI1 protein in the group without lymph node metastasis was higher than that in group with lymph node metastasis (P＜0.05). There was no difference in positive expression rate of KAI1 protein for male or female patients (P ＞0. 05). KAI1 protein expression in papillary thyroid carcinoma was not related to patients' ages, tumor size, TNM staging or capsule invasion (P ＞ 0. 05). Conclusions The abnormal expression of KAI1 mRNA and protein is correlated to the genesis and progress of papillary thyroid carcinoma,which provides a clue for treatment and prognosis assessment of papillary thyroid carcinoma